Cochrane Netherlands, Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
Research Support, Diakonessenhuis Utrecht, Bosboomstraat 1, 3582 KE, Utrecht, The Netherlands.
Syst Rev. 2022 Sep 5;11(1):191. doi: 10.1186/s13643-022-02053-9.
With the exponential growth of published systematic reviews (SR), there is a high potential for overlapping and redundant duplication of work. Prospective protocol registration gives the opportunity to assess the added value of a new study or review, thereby potentially reducing research waste and simultaneously increasing transparency and research quality. The PROSPERO database for SR protocol registration was launched 10 years ago. This study aims to assess the proportion SRs of intervention studies with a protocol registration (or publication) and explore associations of SR characteristics with protocol registration status.
PubMed was searched for SRs of human intervention studies published in January 2020 and January 2021. After random-stratified sampling and eligibility screening, data extraction on publication and journal characteristics, and protocol registration status, was performed. Both descriptive and multivariable comparative statistical analyses were performed.
A total of 357 SRs (2020: n = 163; 2021: n = 194) were included from a random sample of 1267 publications. Of the published SRs, 38% had a protocol. SRs that reported using PRISMA as a reporting guideline had higher odds of having a protocol than publications that did not report PRISMA (OR 2.71; 95% CI: 1.21 to 6.09). SRs with a higher journal impact factor had higher odds of having a protocol (OR 1.12; 95% CI 1.04 to 1.25). Publications from Asia had a lower odds of having a protocol (OR 0.43; 95% CI 0.23 to 0.80, reference category = Europe). Of the 33 SRs published in journals that endorse PROSPERO, 45% did not have a protocol. Most SR protocols were registered in PROSPERO (n = 129; 96%).
We found that 38% of recently published SRs of interventions reported a registered or published protocol. Protocol registration was significantly associated with a higher impact factor of the journal publishing the SR and a more frequent self-reported use of the PRISMA guidelines. In some parts of the world, SR protocols are more often registered or published than others. To guide strategies to increase the uptake of SR protocol registration, further research is needed to gain understanding of the benefits and informativeness of SRs protocols among different stakeholders.
osf.io/9kj7r/.
随着发表的系统评价（SR）数量呈指数级增长，工作可能存在大量重叠和冗余。前瞻性方案注册使评估新研究或综述的附加值成为可能，从而有可能减少研究浪费，同时提高透明度和研究质量。PROSPERO 数据库用于 SR 方案注册于 10 年前推出。本研究旨在评估具有方案注册（或发表）的干预性研究 SR 的比例，并探讨 SR 特征与方案注册状态的关联。
在 2020 年 1 月和 2021 年 1 月期间，在 PubMed 中搜索人类干预性研究的 SR。经过随机分层抽样和资格筛选，对发表和期刊特征以及方案注册状态进行数据提取。进行描述性和多变量比较统计分析。
从 1267 篇出版物中随机抽取的样本中，共纳入 357 篇 SR（2020 年：n=163；2021 年：n=194）。已发表的 SR 中有 38%有方案。报告使用 PRISMA 作为报告指南的 SR 比未报告 PRISMA 的出版物更有可能有方案（OR 2.71；95%CI：1.21 至 6.09）。期刊影响因子较高的 SR 更有可能有方案（OR 1.12；95%CI 1.04 至 1.25）。来自亚洲的出版物方案注册的可能性较低（OR 0.43；95%CI 0.23 至 0.80，参考类别=欧洲）。在发表于支持 PROSPERO 的期刊的 33 篇 SR 中，45%没有方案。大多数 SR 方案在 PROSPERO 中注册（n=129；96%）。
我们发现，最近发表的干预性 SR 中有 38%报告了已注册或已发表的方案。方案注册与发表 SR 的期刊影响因子较高以及更频繁地自我报告使用 PRISMA 指南显著相关。在世界某些地区，SR 方案的注册或发表比其他地区更为常见。为了指导增加 SR 方案注册的策略，需要进一步研究，以了解不同利益相关者对 SR 方案的益处和信息量的看法。
osf.io/9kj7r/。
